Search or filter publications

Filter by type:

Filter by publication type

Filter by year:

to

Results

  • Showing results for:
  • Reset all filters

Search results

  • Journal article
    Ito K, Barnes PJ, 2025,

    COPD as a disease of accelerated lung aging

    , REVISTA PORTUGUESA DE PNEUMOLOGIA, Vol: 15, Pages: 743-746, ISSN: 0873-2159
  • Journal article
    Chung KF, 2025,

    A silent revolution: phenotyping asthma for personalised medicine

    , REVISTA PORTUGUESA DE PNEUMOLOGIA, Vol: 21, Pages: 293-294, ISSN: 0873-2159
  • Journal article
    Pham DD, Lee J-H, Kwon H-S, Song W-J, Cho YS, Kim H, Kwon J-W, Park S-Y, Kim S, Hur GY, Kim BK, Nam Y-H, Yang M-S, Kim M-Y, Kim S-H, Lee B-J, Lee T, Park SY, Kim M-H, Cho Y-J, Park C, Jung J-W, Park HK, Kim J-H, Moon J-Y, Bhavsar P, Adcock I, Chung KF, Kim T-Bet al., 2025,

    Concurrent blood eosinophils and FeNO as biological therapy indicators in severe asthma: findings from the PRISM study

    , The Journal of Allergy and Clinical Immunology: In Practice, ISSN: 2213-2198

    BackgroundThe combination of pretreatment peripheral blood eosinophil count (BEC) and FeNO levels for optimizing the therapeutic response of T2-biologics in patients with severe eosinophilic asthma (SEA) remains unclear.ObjectiveTo compare longitudinal clinical outcome changes across subgroups stratified by the combination of high and low levels of BEC and FeNO.MethodsOverall, 278 patients with SEA (anti-IL-5/IL-5Rα users: n = 82; and anti-IL-4Rα users: n = 196) were stratified based on pretreatment BEC and FeNO levels and observed for 6 to 12 months. Group differences in exacerbation rate, lung function, Asthma Control Test, BEC, FeNO, and clinical remission over time were compared.ResultsApproximately 75% and 63% of patients presented with concurrent high BEC (≥300 cells/μL) and high FeNO (≥25 ppb) in the anti-IL-5/IL-5Rα and anti-IL-4Rα groups, respectively. Among anti-IL-5/IL-5Rα users, we observed no significant differences among BEC-FeNO groups regarding exacerbation rates or clinical remission. Patients with concurrent high BEC and FeNO levels demonstrated more pronounced reductions in both markers and greater FEV1 and Asthma Control Test score improvements compared with those with high FeNO but low BEC. In the anti-IL-4Rα group, patients with low BEC and FeNO, and those with high BEC but low FeNO, exhibited a significantly lower likelihood of achieving clinical remission (odds ratio [95% CI]: 0.08 [0.00-0.46] and 0.11 [0.01-0.63], respectively) and a slower rate of FEV1 improvement (all P for slope < .05) compared with those with concurrent high BEC and FeNO.ConclusionConcurrently elevated BEC and FeNO levels ensure optimal therapeutic response in patients with SEA who are treated with T2 biologics.Key wordsSevere eosinophilic asthmaBlood eosinophil countFeNOBiologicsAbbreviations usedACTAsthma Control TestBECBlood eosinophil countICSInhaled corticosteroidsNBNegative binomialOCSOral corticosteroidsPRISMPrecisio
  • Journal article
    Edwards DA, Edwards A, Li D, Wang L, Chung KF, Bhatta D, Bilstein A, Hanes J, Endirisinghe I, Freeman BB, Gutay M, Livraghi-Butrico A, Button Bet al., 2025,

    Global warming risks dehydrating and inflaming human airways

    , COMMUNICATIONS EARTH & ENVIRONMENT, Vol: 6
  • Journal article
    Grillo L, Schreuder F, Izzie E, Chloe B, Hopkinson N, Shannon H, Anne-Marie Ret al., 2025,

    Physiotherapy assessment of breathlessness and disordered patterns of breathing: defining a consensus on terminology and assessment

    , Chronic Respiratory Disease, ISSN: 1479-9723

    Introduction: Abnormal breathing patterns unexplained by pathophysiology are typically referred to using terms including chronic breathlessness syndrome or complex breathlessness. Often patients with these conditions are referred to physiotherapy for an assessment of this breathlessness, where some are diagnosed with breathing pattern disorder (BrPD) or dysfunctional breathing (DB). The condition seen in physiotherapy occurs in at least 10% of the general population, increasing to 29−40% with coexisting conditions. Inconsistency in the nomenclature and physiotherapy assessment reduces recognition of the condition and hinders development in this area. Aims of the study: To establish expert physiotherapists' consensus on terminology to describe this condition and provide guidance for its physiotherapy assessment. Participants and methods: The opinions and experiences of ten respiratory physiotherapists, nine other clinicians (doctors, nurses, and speech and language therapists), and five patients diagnosed with BrPD were explored in focus groups or interviews regarding the terminology used and assessment experience. A second separate purposive sample of clinical expert physiotherapists (n = 11) took part in a nominal group technique (NGT) process to build consensus on the following questions: Question 1: What is your preferred term for this condition? Question 2: What are the most important assessment components to be included in all assessments? Results: One focus group (n = 10) and 14 interviews were completed. Framework analysis of the data from focus groups and interviews was undertaken and these results were shared with the participants in the nominal group. Consensus (71%) for the term breathing pattern disorder (BrPD) was achieved and an assessment guide was created. Conclusion: With improved consistency in its description and assessment, the adoption of breathing pattern disorder may help to further develop clinical and research priorities in this area w
  • Journal article
    Bousquet J, Sousa-Pinto B, Anto JM, Amaral R, Brussino L, Canonica GW, Cruz AA, Gemicioglu B, Haahtela T, Kupczyk M, Kvedariene V, Larenas-Linnemann DE, Louis R, Pham-Thi N, Puggioni F, Regateiro FS, Romantowski J, Sastre J, Scichilone N, Taborda-Barata L, Ventura MT, Agache I, Bedbrook A, Bergmann KC, Bosnic-Anticevich S, Bonini M, Boulet LP, Brusselle G, Buhl R, Cecchi L, Charpin D, Chaves-Loureiro C, Czarlewski W, de Blay F, Devillier P, Joos G, Jutel M, Klimek L, Kuna P, Laune D, Pech JL, Makela M, Morais-Almeida M, Nadif R, Niedoszytko M, Ohta K, Papadopoulos NG, Papi A, Yeverino DR, Roche N, Sa-Sousa A, Samolinski B, Shamji MH, Sheikh A, Ulrik CS, Usmani OS, Valiulis A, Vandenplas O, Yorgancioglu A, Zuberbier T, Fonseca JAet al., 2025,

    Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app

    , PULMONOLOGY, Vol: 29, Pages: 292-305, ISSN: 2531-0437
  • Journal article
    Liu G, Hsu AC, Geirnaert S, Cong C, Nair PM, Shen S, Marshall JE, Haw TJ, Fricker M, Philp AM, Hansbro NG, Pavlidis S, Guo Y, Burgess JK, Castellano L, Ieni A, Caramori G, Oliver BGG, Chung KF, Adcock IM, Knight DA, Polverino F, Bracke K, Wark PA, Hansbro PMet al., 2025,

    Vitronectin regulates lung tissue remodeling and emphysema in chronic obstructive pulmonary disease

    , MOLECULAR THERAPY, Vol: 33, Pages: 917-932, ISSN: 1525-0016
  • Journal article
    Matera MG, Calzetta L, Rinaldi B, de Novellis V, Page CP, Barnes PJ, Cazzola Met al., 2025,

    Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review

    , EXPERT OPINION ON DRUG DISCOVERY, Vol: 20, Pages: 337-356, ISSN: 1746-0441
  • Journal article
    Montuschi P, Adcock IM, 2025,

    Protein tyrosine phosphatase 4A3 inhibition: A new pharmacological strategy for acute lung injury?

    , JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol: 392, ISSN: 0022-3565
  • Journal article
    Bloom C, Middleton J, Lewis A, 2025,

    Qualitative study of patients experiences and perceptions of stepping down asthma medication in primary care across England

    , BMJ Open Respiratory Research, Vol: 12, ISSN: 2052-4439

    BackgroundGuidelines recommend that asthma medication should be stepped down to the minimally effective dose that achieves symptom control. Stepping down aims to prevent adverse medication effects and unnecessary costs but is often not implemented in primary care, where most asthma patients are managed. Little is known about the experiences and views of patients regarding stepping down. MethodsStable asthma patients, with regular use of a preventer inhaler, from GP practices across England, participated in a survey and/or semi-structured interview. Questions explored the patient’s understanding of their asthma, views and knowledge of preventer inhalers, experiences and perceptions of stepping down asthma medication. Qualitative group-based multi-disciplinary thematic analysis by two healthcare professionals and a patient were performed.Results143 patients responded to the survey, 63% were female, between the ages 18-80 years, and including geographical areas across the UK, 17 of whom participated in an interview. Half of these stable asthma patients, most with asthma for more than 10 years, had never had a discussion regarding stepping down asthma medication. Most stepping down that had occurred was related to seasonal changes in asthma control. Four overarching themes from the interviews were identified, (i) experiences of living with asthma and needing inhalers, (ii) insufficient education regarding preventer inhalers, (ii) stepping down is agreeable and possible and (iv) current asthma care is suboptimal.ConclusionStable asthma patients were able to self-manage their asthma well. They had little awareness of medication adverse effects and minimal experience of having their medication stepped down by a healthcare professional. Most were inclined to step down, if clinically safe to do so, indeed some had reduced their medication doses themselves, without professional guidance.
  • Conference paper
    Rathnayake S, Idrees S, Brandsma C, Oliver B, Timens W, Adcock I, Nawijn M, Heijink I, Van den Berge M, Faiz Aet al., 2025,

    IMPACT OF TSLP ON GENE EXPRESSION IN HUMAN AIRWAY EPITHELIAL CELLS

    , Publisher: WILEY, Pages: 16-16, ISSN: 1444-0903
  • Conference paper
    Chung L, Thompson B, Siddiqui S, Usmani O, Farah Cet al., 2025,

    INTERPRETING RESPIRATORY OSCILLOMETRY IN ADULTS WITH ASTHMA OR COPD: FINDINGS OF AN INTERNATIONAL DELPHI STUDY

    , Publisher: WILEY, Pages: 80-81, ISSN: 1444-0903
  • Journal article
    Sousa-Pinto B, Costa EM, Vieira RJ, Klimek L, Czarlewski W, Pfaar O, Bedbrook A, Amaral R, Brussino L, Kvedariene V, Larenas-Linnemann DE, Iinuma T, Pham-Thi N, Regateiro FS, Taborda-Barata L, Ventura MT, Ansotegui IJ, Bergmann KC, Canonica GW, Cardona V, Cecchi L, Cherrez-Ojeda I, Cingi C, Cruz AA, Del Giacco S, Devillier P, Fokkens WJ, Gemicioglu B, Haahtela T, Ivancevich JC, Kuna P, Kraxner H, Laune D, Louis R, Makris M, Morais-Almeida M, Moesges R, Niedoszytko M, Papadopoulos NG, Patella V, Pereira AM, Reitsma S, Robles-Velasco K, Rouadi PW, Samolinski B, Sova M, Toppila-Salmi SK, Sastre J, Valiulis A, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, Bousquet Jet al., 2025,

    Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-air Study

    , CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 55, Pages: 226-238, ISSN: 0954-7894
  • Journal article
    Liu M, Yao X, Shi Y, Liu H, Chen L, Lu Y, Zhang C, Zhang X, Liang L, Chang X, An L, Chung KF, Kocks JWH, Huang Ket al., 2025,

    Impulse oscillometry-derived equation for prediction of abnormal FEV1/FVC ratio for COPD screening in Chinese population: a multicenter cross-sectional study

    , LANCET REGIONAL HEALTH-WESTERN PACIFIC, Vol: 56
  • Journal article
    Laanesoo A, Mae M, Remm A, Johnston SL, Altraja A, Bochenek G, Jakiela B, Rebane Aet al., 2025,

    NLRP1 Is a Prominent Inflammasome Sensor Found in Bronchial Epithelial Cells in Asthma and Can Be Activated by Rhinovirus A16

    , CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 55, Pages: 239-246, ISSN: 0954-7894
  • Journal article
    Hopkinson N, 2025,

    Chronic obstructive pulmonary disease: new therapies and old needs

    , LANCET RESPIRATORY MEDICINE, Vol: 13, Pages: 193-194, ISSN: 2213-2600
  • Journal article
    Lee HY, Lee Y, Lee S-E, Sim DW, Kang N, Lee B-J, Kim J-H, Kang S-Y, Kim S, Oh JH, Sohn K-H, Park H-K, Kim SR, Kim M-H, Park H-K, Park S-Y, Kwon J-W, Park H-S, Kim S-H, Cho YS, Chung KF, Song W-Jet al., 2025,

    Relationships Between Chronic Cough and Asthma Control and Quality of Life in Patients With Severe Asthma: A 6-Month Longitudinal Analysis

    , JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, Vol: 13, ISSN: 2213-2198
  • Journal article
    Khaleva E, Brightling C, Eiwegger T, Altraja A, Begin P, Blumchen K, Bossios A, Bourdin A, Ten Brinke A, Brusselle G, Bumbacea RS, Bush A, Casale TB, Clarke GW, Chaudhuri R, Chung KF, Coleman C, Corren J, Dahlen S-E, Deschildre A, Djukanovic R, Eger K, Exley A, Fleming L, Fowler SJ, Gaillard EA, Gappa M, Gupta A, Haitchi HM, Hashimoto S, Heaney LG, Hedlin G, Henderson M, Hua W, Jackson DJ, Karadag B, Katelaris CH, Koh MS, Kopp MV, Koppelman GH, Kull I, Kurukulaaratchy RJ, Lee J-H, Mahler V, Makela M, Masoli M, Mathioudakis AG, Mazon A, Melen E, Milger K, Moeller A, Murray CS, Nagakumar P, Nair P, Negus J, Nieto A, Papadopoulos NG, Paton J, Pijnenburg MW, Pike KC, Porsbjerg C, Rattu A, Rupani H, Rusconi F, Rutjes NW, Saglani S, Seddon P, Siddiqui S, Singer F, Tajiri T, Turner S, Upham JW, Vijverberg SJH, Wark PAB, Wechsler ME, Yasinska V, Roberts Get al., 2025,

    Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma

    , EUROPEAN RESPIRATORY JOURNAL, Vol: 65, ISSN: 0903-1936
  • Journal article
    Khalaf Z, Saglani S, Bloom CI, 2025,

    Implementation and Effectiveness of Guideline-Recommended Clinical Activities for Children With Asthma Population-Based Cohort

    , CHEST, Vol: 167, ISSN: 0012-3692
  • Journal article
    Agache I, Annesi-Maesano I, Cecchi L, Biagioni B, Chung F, D'Amato G, Damialis A, del Giacco S, Dominguez Ortega J, Galan C, Gilles S, Holgate S, Jeebhay M, Kazadzis S, Nadeau K, Papadopoulos NG, Quirce S, Sastre J, Traidl-Hoffmann C, Walusiak-Skorupa J, Zemelka-Wiacek M, Jutel M, Akdis CAet al., 2025,

    EAACI Guidelines on Environmental Science for Allergy and Asthma-Recommendations on the Impact of Indoor Air Pollutants on the Risk of New-Onset Asthma and on Asthma-Related Outcomes

    , ALLERGY, ISSN: 0105-4538

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://www.imperial.ac.uk:80/respub/WEB-INF/jsp/search-t4-html.jsp Request URI: /respub/WEB-INF/jsp/search-t4-html.jsp Query String: id=854&limit=20&resgrpMemberPubs=true&page=8&respub-action=search.html Current Millis: 1768546443939 Current Time: Fri Jan 16 06:54:03 GMT 2026